Personalis Stock Falls on Preliminary 4Q Results

Dow Jones

01/09

By Emon Reiser

Shares for Personalis fell despite ample cash on hand and a surge in clinical test revenue, according to a preliminary fourth-quarter report released Thursday.

The stock declined 12.6% to $8.17 a share. Despite the intraday decline, shares are up 2.7% year to date.

Personalis said it expects between $17 million and $18 million in fourth-quarter revenue, on par with the $17.5 million analysts expect.

The company said its preliminary clinical test revenue for the quarter is about $900,000 from 6,183 clinical tests in the fourth quarter, compared with about $200,000 in clinical test revenue in the year-ago period.

"Securing Medicare coverage for breast cancer surveillance in the fourth quarter was a pivotal milestone that transforms our commercial trajectory," said Chief Executive Chris Hall. "With a fortified balance sheet of [about] $240 million of cash, we enter 2026 with the capital and the clinical evidence required to expand our sales footprint, secure reimbursement coverage for additional indications, and continue to execute on our Win-in-MRD strategy."

Write to Emon Reiser at emon.reiser@wsj.com

(END) Dow Jones Newswires

January 08, 2026 14:33 ET (19:33 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2602539714"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602539714\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602539714?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 03:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602539714","market":"fut","top_or_hot":-1,"title":"Personalis Stock Falls on Preliminary 4Q Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Emon Reiser \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Shares for <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> fell despite ample cash on hand and a surge in clinical test revenue, according to a preliminary fourth-quarter report released Thursday. \n</p>\n<p>\n  The stock declined 12.6% to $8.17 a share. Despite the intraday decline, shares are up 2.7% year to date. \n</p>\n<p>\n  Personalis said it expects between $17 million and $18 million in fourth-quarter revenue, on par with the $17.5 million analysts expect. \n</p>\n<p>\n  The company said its preliminary clinical test revenue for the quarter is about $900,000 from 6,183 clinical tests in the fourth quarter, compared with about $200,000 in clinical test revenue in the year-ago period. \n</p>\n<p>\n  \"Securing Medicare coverage for breast cancer surveillance in the fourth quarter was a pivotal milestone that transforms our commercial trajectory,\" said Chief Executive Chris Hall. \"With a fortified balance sheet of [about] $240 million of cash, we enter 2026 with the capital and the clinical evidence required to expand our sales footprint, secure reimbursement coverage for additional indications, and continue to execute on our Win-in-MRD strategy.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Emon Reiser at emon.reiser@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 14:33 ET (19:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Personalis Stock Falls on Preliminary 4Q Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPersonalis Stock Falls on Preliminary 4Q Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-09 03:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Emon Reiser \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Shares for <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> fell despite ample cash on hand and a surge in clinical test revenue, according to a preliminary fourth-quarter report released Thursday. \n</p>\n<p>\n  The stock declined 12.6% to $8.17 a share. Despite the intraday decline, shares are up 2.7% year to date. \n</p>\n<p>\n  Personalis said it expects between $17 million and $18 million in fourth-quarter revenue, on par with the $17.5 million analysts expect. \n</p>\n<p>\n  The company said its preliminary clinical test revenue for the quarter is about $900,000 from 6,183 clinical tests in the fourth quarter, compared with about $200,000 in clinical test revenue in the year-ago period. \n</p>\n<p>\n  \"Securing Medicare coverage for breast cancer surveillance in the fourth quarter was a pivotal milestone that transforms our commercial trajectory,\" said Chief Executive Chris Hall. \"With a fortified balance sheet of [about] $240 million of cash, we enter 2026 with the capital and the clinical evidence required to expand our sales footprint, secure reimbursement coverage for additional indications, and continue to execute on our Win-in-MRD strategy.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Emon Reiser at emon.reiser@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 14:33 ET (19:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSNL","symbol_name":"Personalis","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602539714","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602539714","pubTimestamp":1767900780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares for Personalis fell despite ample cash on hand and a surge in clinical test revenue, according to a preliminary fourth-quarter report released Thursday.The stock declined 12.6% to $8.17 a share. Despite the intraday decline, shares are up 2.7% year to date.Personalis said it expects between $17 million and $18 million in fourth-quarter revenue, on par with the $17.5 million analysts expect.The company said its preliminary clinical test revenue for the quarter is about $900,000 from 6,183 clinical tests in the fourth quarter, compared with about $200,000 in clinical test revenue in the year-ago period.\"Securing Medicare coverage for breast cancer surveillance in the fourth quarter was a pivotal milestone that transforms our commercial trajectory,\" said Chief Executive Chris Hall. \"With a fortified balance sheet of [about] $240 million of cash, we enter 2026 with the capital and the clinical evidence required to expand our sales footprint, secure reimbursement coverage for additio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PSNL":"Personalis","BK4121":"生命科学工具和服务"},"translate_title":"Personalis股价因第四季度初步业绩而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSNL":1.5},"content_text":"By Emon Reiser \n\n\n \n\n\n   Shares for Personalis fell despite ample cash on hand and a surge in clinical test revenue, according to a preliminary fourth-quarter report released Thursday. \n\n\n  The stock declined 12.6% to $8.17 a share. Despite the intraday decline, shares are up 2.7% year to date. \n\n\n  Personalis said it expects between $17 million and $18 million in fourth-quarter revenue, on par with the $17.5 million analysts expect. \n\n\n  The company said its preliminary clinical test revenue for the quarter is about $900,000 from 6,183 clinical tests in the fourth quarter, compared with about $200,000 in clinical test revenue in the year-ago period. \n\n\n  \"Securing Medicare coverage for breast cancer surveillance in the fourth quarter was a pivotal milestone that transforms our commercial trajectory,\" said Chief Executive Chris Hall. \"With a fortified balance sheet of [about] $240 million of cash, we enter 2026 with the capital and the clinical evidence required to expand our sales footprint, secure reimbursement coverage for additional indications, and continue to execute on our Win-in-MRD strategy.\" \n\n\n \n\n\n   Write to Emon Reiser at emon.reiser@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 14:33 ET (19:33 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}